The DOI matches its Crossref record; 88 of the 90 references it cites were found in a registry or an index; none of the 52 sources its claims cite is checked for support yet.
Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy
Open accessAbstract
The development of viral vectors has been particularly critical for genetic therapies of hematological diseases. Before the development of retrovirus vectors (RVVs), gene transfer into mammalian cells was accomplished by transduction of DNA plasmids by chemical means and later by electroporation. The main limitation of these methods is the inefficiency of transfer of intact sequences, and particularly with electroporation significant cell death of the manipulated cells. The earliest successful human gene therapy trials utilized γ-RVVs and many of the techniques developed in the 1980s. A breakthrough for the field was the exploitation and development of HIV for transfer vectors, termed lentivirus vectors. In this review, we highlight uses of retro- and lentivirus vectors in monogenic diseases in which hematopoietic stem cells are used in the autologous setting to treat immunodeficiencies, hemoglobinopathies and metabolic diseases. The three authors' perspective represent experiences in the field over four decades that encompasses both basic translational research and development and oversight of early and ongoing gene therapy trials utilizing viral vectors.
Overview
CoChat Summary
Written by AI from the paper’s full text.
TL;DR
This review summarizes four decades of ex vivo hematopoietic stem and progenitor cell (HSPC) gene therapy using γ-retroviral and lentiviral vectors for immunodeficiencies, hemoglobinopathies, and metabolic/lysosomal diseases. It highlights curative clinical results, the shift to lentiviral vectors, and persistent risks including insertional oncogenesis, manufacturing complexity, and limited access.
Key findings
- Lentiviral vectors (LVVs) have become the predominant HSPC gene-transfer platform, with hundreds of patients treated safely and three LVV products recently FDA-approved for HSC gene therapies; γ-retroviral vectors remain useful but carry enhancer-driven insertional oncogenesis risk.
- In ADA-SCID, γ-retroviral HSC gene therapy treated more than 60 patients, with one vector-related T cell leukemia; a SIN LVV ADA-SCID therapy reported 50 treated patients with 100% survival, 96% event-free survival, 2 engraftment failures, and no insertional events out to 6–11 years.
- In XSCID, 20 patients treated with γ-retroviral vectors had high immune restoration but a significant number developed T leukoproliferative complications; subsequent SIN γ-retroviral and SIN LVV approaches treated 9 and more than 30 patients, respectively, with immune reconstitution and no clonal expansion.
- For metabolic and hemoglobin disorders, cALD gene therapy in 32 patients showed benefit at median 6-year follow-up but was complicated by insertional mutagenesis and hematological malignancy; MLD therapy in 29 pediatric patients had 26 alive at median 3.16 years (range 0.64–7.51), and MPS I therapy in 8 patients showed metabolic correction at median 2.1 years.
Methods
- Narrative review by three authors with four decades of experience in basic, translational, and clinical HSPC gene therapy.
- Evidence drawn from preclinical animal models, early and ongoing human gene therapy trials, long-term follow-up studies, and approved products for immunodeficiencies, leukodystrophies, mucopolysaccharidoses, and hemoglobinopathies.
- No systematic search strategy, meta-analysis, or new primary data collection is described.
Limitations
- Stated in the paper: high financial costs and commercialization challenges limit gene therapy for rare and ultra-rare diseases; manufacturing of LVVs remains complex and can cause pipeline delays; cytotoxic conditioning is still needed for high-level engraftment; access to approved therapies remains limited; follow-up for gene-editing approaches is short and few patients have been treated.
- Evident from the text: this is a narrative review rather than a systematic review, so selection and emphasis may reflect the authors’ perspectives and experience.
- Evident from the text: the authors report multiple financial and advisory conflicts of interest, including founderships, equity, consulting, and vector licensing relationships with gene therapy companies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
28 Own interpretation · 18 Check pending · 10 No full text of the sources · 10 Not checked yet · 7 No basis given · 2 Sources not found · 1 Own result
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“These enhancer sequences unfortunately were also implicated in insertional oncogenesis that developed in the very first successful trial in severe combined immunodeficiency (SCID) and later in other trials.15,16”
§ Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites [15] Hacein-Bey-Abina, 2003, LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1, Science source
- Not checked — no full text of the sourcecites [16] Howe, 2008, Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients, J. Clin. Invest. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The development of viral vectors has been particularly critical for genetic therapies of hematological diseases.”
§ Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy > Abstract
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“HSCs are both rare and typically quiescent cells and early on it became apparent that murine HSCs were more efficiently transduced using viral vectors than human HSCs.”
§ Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy > INTRODUCTION
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“γ-RVVs require cell division for efficient integration into the host genome.”
§ Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy > INTRODUCTION
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Thus, the major breakthrough in the field was adoption of γ-retroviruses as vectors to transfer DNA into HSPCs (Figure 1).4,5”
§ Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites [4] Williams, 1984, Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse, Nature source
- Not checked — no full text of the sourcecites [5] Dick, 1985, Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice, Cell source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 13
- It may state two separate claims as one. 38
- The quote only partly states this claim. 1
Create a free account to see these claims.
Create a free account to see these assumptions.
26 more claims
Create a free account to see all 76 claims and to verify the 33 references still open.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy > VIRAL VECTORS USE IN GENE THERAPY FOR HEMOGLOBINOPATHIES
“leading to the incorporation of shRNA targeting knockdown of BCL11 in LVV in clinical trials by the Williams laboratory [81][82][83][84]”
§ Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy > References
“81. Guda, S.A., Guda, A.A., Soldatov, M.A., Lomachenko, K.A., Bugaev, A.L., Lamberti, C., Gawelda, W., Bressler, C., Smolentsev, G., Soldatov, A.V., and Joly, Y. (2015). Optimized Finite Difference Method for the Full-Potential XANES Simulations: Application to Molecular Adsorption Geometries in MOFs and Metal-Ligand Intersystem Crossing Transients.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy > CHRONIC GRANULOMATOUS DISEASE
“A first patient has been treated at Great Ormond Street Hospital with good early results.41”
§ Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy > References
“41. Aguila, H.N., Lai, W.C., Lu, Y.S., and Pakes, S.P. (1988). Experimental Mycoplasma pulmonis infection of rats suppresses humoral but not cellular immune response. Lab. Anim. Sci. 38, 138-142.”
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167
Mann, R., Mulligan, R. C., & Baltimore, D. (1983) · Cell · doi:10.1016/0092-8674(83)90344-6 · Cited by 1,776
T Lymphocyte-Directed Gene Therapy for ADA − SCID: Initial Trial Results After 4 Years
Blaese, R. M., Culver, K. W., Miller, A. D., Carter, C. S., Fleisher, T. A., Clerici, M., Shearer, G. M., Chang, L., Chiang, Y. L., Tolstoshev, P., et al. (1995) · Science · doi:10.1126/science.270.5235.475 · Cited by 1,546
Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells
Wigler, M. H., Silverstein, S. J., Lee, L., Pellicer, À., Cheng, Y., & Axel, R. (1977) · Cell · doi:10.1016/0092-8674(77)90333-6 · Cited by 1,352
Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration
Wu, X., Li, Y., Crise, B., & Burgess, S. M. (2003) · Science · doi:10.1126/science.1083413 · Cited by 1,305
Howe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35798 · Cited by 1,286
Self-citationTransfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Self-citationLentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., et al. (2013) · Science · doi:10.1126/science.1233151 · Cited by 1,025
Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning
Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., et al. (2002) · Science · doi:10.1126/science.1070104 · Cited by 975
Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A
Sankaran, V. G., Menne, T. F., Xu, J., Akie, T. E., Lettre, G., Van Handel, B., Mikkola, H. K. A., Hirschhorn, J. N., Cantor, A. B., & Orkin, S. H. (2008) · Science · doi:10.1126/science.1165409 · Cited by 919
Stein, S., Ott, M. G., Schultze-Strasser, S., Jauch, A., Burwinkel, B., Kinner, A., Schmidt, M., Krämer, A., Schwäble, J., Glimm, H., et al. (2010) · Nature Medicine · doi:10.1038/nm.2088 · Cited by 716
Self-citationGene therapy in a patient with sickle cell disease
Ribeil, J.-A., Hacein-Bey-Abina, S., Payen, E., Magnani, A., Semeraro, M., Magrin, E., Caccavelli, L., Neven, B., Bourget, P., El Nemer, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609677 · Cited by 696
An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level
Bauer, D. E., Kamran, S. C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M. C., Smith, E. C., Pinello, L., et al. (2013) · Science · doi:10.1126/science.1242088 · Cited by 653
Correction of sickle cell disease in transgenic mouse models by gene therapy
Pawliuk, R., Westerman, K. A., Fabry, M. E., Payen, E., Tighe, R., Bouhassira, E. E., Acharya, S. A., Ellis, J., London, I. M., Eaves, C. J., et al. (2001) · Science · doi:10.1126/science.1065806 · Cited by 579
May, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M. (2000) · Nature · doi:10.1038/35017565 · Cited by 567
Gene therapy for Wiskott-Aldrich syndrome–long-term efficacy and genotoxicity
Braun, C. J., Boztug, K., Paruzynski, A., Witzel, M., Schwarzer, A., Rothe, M., Modlich, U., Beier, R., Göhring, G., Steinemann, D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007280 · Cited by 562
The 2022 Update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity
Bousfiha, A. A., Moundir, A., Tangye, S. G., Pïcard, C., Jeddane, L., Al–Herz, W., Rundles, C. C., Franco, J. L., Holland, S. M., Klein, C., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01352-z · Cited by 548
Hanenberg, H., Xiao, X. L., Dilloo, D., Hashino, K., Kato, I., & Williams, D. A. (1996) · Nature Medicine · doi:10.1038/nm0896-876 · Cited by 543
Self-citationHighly efficient therapeutic gene editing of human hematopoietic stem cells
Wu, Y., Zeng, J., Roscoe, B. P., Liu, P., Yao, Q., Lazzarotto, C. R., Clement, K., Cole, M. A., Luk, K., Baricordi, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0401-y · Cited by 515
Self-citationPost-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease
Esrick, E. B., Lehmann, L. E., Biffi, A., Achebe, M., Brendel, C., Ciuculescu, M. F., Daley, H., MacKinnon, B., Morris, E., Federico, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029392 · Cited by 449
Self-citationDick, J. E., Magli, M. C., Huszar, D., Phillips, R. A., & Bernstein, A. (1985) · Cell · doi:10.1016/s0092-8674(85)80102-1 · Cited by 446
A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency
Hacein-Bey-Abina, S., Pai, S.-Y., Gaspar, H. B., Armant, M., Berry, C. C., Blanche, S., Bleesing, J., Blondeau, J., de Boer, H., Buckland, K. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404588 · Cited by 412
Self-citationIntroduction of new genetic material into pluripotent haematopoietic stem cells of the mouse
Williams, D. A., Lemischka, I. R., Nathan, D. G., & Mulligan, R. C. (1984) · Nature · doi:10.1038/310476a0 · Cited by 388
Self-citationMiller, A. D. (1990) · Human Gene Therapy · doi:10.1089/hum.1990.1.1-5 · Cited by 382
Correction of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin Silencing
Xu, J., Peng, C., Sankaran, V. G., Shao, Z., Esrick, E. B., Chong, B. G., Ippolito, G. C., Fujiwara, Y., Ebert, B. L., Tucker, P. W., et al. (2011) · Science · doi:10.1126/science.1211053 · Cited by 326
Fumagalli, F., Calbi, V., Natali Sora, M. G., Sessa, M., Baldoli, C., Rancoita, P. M. V., Ciotti, F., Sarzana, M., Fraschini, M., Zambon, A. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02017-1 · Cited by 298
Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1
Mamcarz, E., Zhou, S., Lockey, T., Abdelsamed, H., Cross, S. J., Kang, G., Ma, Z., Condori, J., Dowdy, J., Triplett, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815408 · Cited by 263
De Ravin, S. S., Li, L., Wu, X., Choi, U., Allen, C., Koontz, S., Lee, J., Theobald-Whiting, N., Chu, J., Garofalo, M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3480 · Cited by 258
Lentiviral gene therapy for X-linked chronic granulomatous disease
the Net4CGD consortium, Kohn, D. B., Booth, C., Kang, E. M., Pai, S.-Y., Shaw, K. L., Santilli, G., Armant, M., Buckland, K. F., Choi, U., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0735-5 · Cited by 248
Self-citationLentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency
De Ravin, S. S., Wu, X., Moir, S., Kardava, L., Anaya-O’Brien, S., Kwatemaa, N., Littel, P., Theobald, N., Choi, U., Su, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8856 · Cited by 244
Guda, S. A., Guda, A. A., Soldatov, M. A., Lomachenko, K. A., Bugaev, A. L., Lamberti, C., Gawełda, W., Bressler, C., Smolentsev, G. Y., Soldatov, A. V., et al. (2015) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.5b00327 · Cited by 228
Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency
Kohn, D. B., Booth, C., Shaw, K. L., Xu-Bayford, J., Garabedian, E., Trevisan, V., Carbonaro-Sarracino, D. A., Soni, K., Terrazas, D., Snell, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2027675 · Cited by 217
Self-citationMoritz, T., Patel, V. P., & Williams, D. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117122 · Cited by 212
Self-citationAcute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease
Goyal, S., Tisdale, J., Schmidt, M., Kanter, J., Jaroscak, J., Whitney, D., Bitter, H., Gregory, P. D., Parsons, G., Foos, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109167 · Cited by 211
Sadelain, M., Wang, C. H., Antoniou, M. N., Grosveld, F. G., & Mulligan, R. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6728 · Cited by 198
Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome
Gentner, B., Tucci, F., Galimberti, S., Fumagalli, F., De Pellegrin, M., Silvani, P., Camesasca, C., Pontesilli, S., Darin, S., Ciotti, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106596 · Cited by 171
Li, L., Moshous, D., Zhou, Y., Wang, J., ., G. X., SALIDO, E. C., Hu, D. C., de Villartay, J., & Cowan, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.12.6323 · Cited by 169
Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype.
Brendel, C., Guda, S., Renella, R., Bauer, D. E., Canver, M. C., Kim, Y.-J., Heeney, M. M., Klatt, D., Fogel, J., Milsom, M. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87885 · Cited by 167
Self-citationGene correction for SCID-X1 in long-term hematopoietic stem cells
Pavel-Dinu, M., Wiebking, V., Dejene, B. T., Srifa, W., Mantri, S., Nicolas, C. E., Lee, C., Bao, G., Kildebeck, E. J., Punjya, N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09614-y · Cited by 167
Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy
Duncan, C. N., Bledsoe, J. R., Grzywacz, B., Beckman, A., Bonner, M., Eichler, F. S., Kühl, J.-S., Harris, M. H., Slauson, S., Colvin, R. A., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2405541 · Cited by 164
Self-citationMiccio, A., Cesari, R., Lotti, F., Rossi, C., Sanvito, F., Ponzoni, M., Routledge, S. J. E., Chow, C.-M., Antoniou, M. N., & Ferrari, G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711666105 · Cited by 154
Santilli, G., Almarza, E., Brendel, C., Choi, U., Beilin, C., Blundell, M. P., Haria, S., Parsley, K. L., Kinnon, C., Malech, H. L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.226 · Cited by 144
Self-citationTargeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome
Hubbard, N., Hagin, D., Sommer, K., Song, Y., Khan, I., Clough, C. A., Ochs, H. D., Rawlings, D. J., Scharenberg, A. M., & Torgerson, T. R. (2016) · Blood · doi:10.1182/blood-2015-11-683235 · Cited by 140
Site-Specific Gene Editing of Human Hematopoietic Stem Cells for X-Linked Hyper-IgM Syndrome
Kuo, C. Y., Long, J. D., Campo-Fernandez, B., de Oliveira, S., Cooper, A. R., Romero, Z., Hoban, M. D., Joglekar, A. V., Lill, G. R., Kaufman, M. L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.103 · Cited by 139
Self-citationKanter, J., Thompson, A. A., Pierciey, F. J., Hsieh, M., Uchida, N., Leboulch, P., Schmidt, M., Bonner, M., Guo, R., Miller, A., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.26741 · Cited by 134
Lentiviral vectors, two decades later
Naldini, L., Trono, D., & Verma, I. M. (2016) · Science · doi:10.1126/science.aah6192 · Cited by 129
Magnani, A., Semeraro, M., Adam, F., Booth, C., Dupré, L., Morris, E. C., Gabrion, A., Roudaut, C., Borgel, D., Toubert, A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01641-x · Cited by 128
Self-citationCRISPR-based gene editing enables FOXP3 gene repair in IPEX patient cells
Goodwin, M., Lee, E., Lakshmanan, U., Shipp, S., Froessl, L. J., Barzaghi, F., Passerini, L., Narula, M., Sheikali, A., Lee, C. M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz0571 · Cited by 116
Perumbeti, A., Higashimoto, T., Urbinati, F., Franco, R. S., Meiselman, H. J., Witte, D. P., & Malik, P. (2009) · Blood · doi:10.1182/blood-2009-01-201863 · Cited by 115
β-globin gene transfer to human bone marrow for sickle cell disease
Romero, Z. G., Urbinati, F., Geiger, S., Cooper, A. R., Wherley, J., Kaufman, M. L., Hollis, R. P., de Assín, R. R., Senadheera, S., Sahagian, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67930 · Cited by 113
Self-citationSergijenko, A., Langford-Smith, A., Liao, A. Y., Pickford, C. E., McDermott, J. H., Nowinski, G., Langford‐Smith, K., Merry, C. L. R., Jones, S. A., Wraith, J. E., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.141 · Cited by 111
Tissue-Specific and Ectopic Expression of Genes Introduced into Transgenic Mice by Retroviruses
Soriano, P. M., Cone, R. D., Mulligan, R. C., & Jaenisch, R. (1986) · Science · doi:10.1126/science.3024318 · Cited by 107
Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy
Eichler, F., Duncan, C. N., Musolino, P. L., Lund, T. C., Gupta, A. O., De Oliveira, S., Thrasher, A. J., Aubourg, P., Kühl, J.-S., Loes, D. J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400442 · Cited by 107
Self-citationRetroviral Integrations in Gene Therapy Trials
Biasco, L., Baricordi, C., & Aiuti, A. (2012) · Molecular Therapy · doi:10.1038/mt.2011.289 · Cited by 106
Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?
Cavazzana, M., Six, E., Lagresle-Peyrou, C., André-Schmutz, I., & Hacein-Bey-Abina, S. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.137 · Cited by 106
Pestina, T. I., Hargrove, P. W., Jay, D. W., Gray, J. T., Boyd, K. L., & Persons, D. A. (2008) · Molecular Therapy · doi:10.1038/mt.2008.259 · Cited by 104
Charrier, S., Dupré, L., Scaramuzza, S., Jeanson-Leh, L., Blundell, M. P., Danos, O., Cattaneo, F., Aiuti, A., Eckenberg, R., Thrasher, A. J., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302863 · Cited by 91
Self-citationMcAuley, G. E., Yiu, G., Chang, P. C., Newby, G. A., Campo-Fernández, B., Fitz‐Gibbon, S. T., Xiaomeng, W., Kang, S.-H. L., Garibay, A., Butler, J., et al. (2023) · Cell · doi:10.1016/j.cell.2023.02.027 · Cited by 90
Self-citationHeffner, G. C., Bonner, M. A., Christiansen, L., Pierciey, F. J., Campbell, D., Smurnyy, Y. D., Zhang, W., Hamel, A., Shaw, S., Lewis, G., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.025 · Cited by 79
Lentiviral Gene Therapy for Artemis-Deficient SCID
Cowan, M. J., Yu, J., Facchino, J., Fraser-Browne, C., Sanford, U., Kawahara, M., Dara, J., Long-Boyle, J., Oh, J., Chan, W., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206575 · Cited by 79
Carbonaro, D. A., Zhang, L., Jin, X., Montiel-Equihua, C., Geiger, S., Carmo, M., Cooper, A., Fairbanks, L., Kaufman, M. L., Sebire, N. J., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.265 · Cited by 78
Self-citationBrendel, C., Negre, O., Rothe, M., Guda, S., Parsons, G., Harris, C., McGuinness, M., Abriss, D., Tsytsykova, A., Klatt, D., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.015 · Cited by 72
Self-citationPoloxamer synperonic F108 improves cellular transduction with lentiviral vectors
Höfig, I., Atkinson, M. J., Mall, S., Krackhardt, A. M., Thirion, C., & Anastasov, N. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2653 · Cited by 69
A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin
Levasseur, D. N., Ryan, T. M., Reilly, M. P., McCune, S. L., Asakura, T., & Townes, T. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402578200 · Cited by 67
Malech, H. L., & Hickstein, D. D. (2007) · Current Opinion in Hematology · doi:10.1097/00062752-200701000-00007 · Cited by 66
Optimal conditions for lentiviral transduction of engrafting human CD34+ cells
Uchida, N., Hsieh, M. M., Hayakawa, J., Madison, C., Washington, K. N., & Tisdale, J. F. (2011) · Gene Therapy · doi:10.1038/gt.2011.63 · Cited by 62
Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID
García-Pérez, L., van Eggermond, M. C. J. A., van Roon, L., Vloemans, S. A., Cordes, M., Schambach, A., Rothe, M., Berghuis, D., Lagresle‐Peyrou, C., Cavazzana, M., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.016 · Cited by 60
Self-citationDe Ravin, S. S., Liu, S., Sweeney, C. L., Brault, J., Whiting-Theobald, N., Ma, M., Liu, T., Choi, U., Lee, J., O’Brien, S. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31344-x · Cited by 51
Li, C. L., Wang, H., Gil, S., Germond, A., Fountain, C., Baldessari, A. E., Kim, J., Liu, Z., Georgakopoulou, A., Radtke, S., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.12.003 · Cited by 49
Kanter, J., Walters, M. C., Hsieh, M. M., Krishnamurti, L., Kwiatkowski, J., Kamble, R. T., von Kalle, C., Kuypers, F. A., Cavazzana, M., Leboulch, P., et al. (2016) · Blood · doi:10.1182/blood.v128.22.1176.1176 · Cited by 47
Morgan, R. A., Unti, M. J., Aleshe, B., Brown, D., Osborne, K. S., Koziol, C., Ayoub, P. G., Smith, O. B., O’Brien, R., Tam, C., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.020 · Cited by 46
Self-citationMigliavacca, M., Barzaghi, F., Fossati, C., Rancoita, P. M. V., Gabaldo, M., Dionisio, F., Giannelli, S., Salerio, F. A., Ferrua, F., Tucci, F., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02789-4 · Cited by 30
Beutler, E. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0486 · Cited by 29
Bzhilyanskaya, V., Ma, L., Liu, S., Fox, L. R., Whittaker, M. N., Meis, R. J., Choi, U., Lawson, A., Ma, M., Theobald, N., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj6779 · Cited by 28
Gray, D. H., Villegas, I., Long, J., Santos, J., Keir, A., Abele, A., Kuo, C. Y., & Kohn, D. B. (2021) · The CRISPR Journal · doi:10.1089/crispr.2020.0080 · Cited by 27
Self-citationPapanikolaou, E., Georgomanoli, M., Stamateris, E., Panetsos, F., Karagiorga, M., Tsaftaridis, P., Graphakos, S., & Anagnou, N. P. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.048 · Cited by 25
Castiello, M. C., Brandas, C., Ferrari, S., Porcellini, S., Sacchetti, N., Canarutto, D., Draghici, E., Merelli, I., Barcella, M., Pelosi, G., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adh8162 · Cited by 25
Consiglieri, G., Tucci, F., Pellegrin, M. D., Guerrini, B., Cattoni, A., Risca, G., Scarparo, S., Sarzana, M., Pontesilli, S., Mellone, R., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adi8214 · Cited by 23
Regulated GATA1 expression as a universal gene therapy for Diamond-Blackfan anemia
Voit, R. A., Liao, X., Caulier, A., Antoszewski, M., Cohen, B., Armant, M. A., Lu, H. Y., Fleming, T. J., Kamal, E., Wahlster, L., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.10.012 · Cited by 23
Self-citationBalancing efficacy and safety in lentiviral vector-mediated hematopoietic stem cell gene therapy
Montini, E., Naldini, L., Booth, C., Kohn, D. B., & Aiuti, A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.028 · Cited by 18
Self-citationAguila, H. N., Lai, W. C., Lu, Y. S., & Pakes, S. P. (1988) · PubMed · Cited by 9
CD34 stem cell stories and lessons from the CD34 wars: the Landsteiner Lecture 2009
Civin, C. I. (2010) · Transfusion · doi:10.1111/j.1537-2995.2010.02729.x · Cited by 8
Ghannam, J. Y., Xu, X., Maric, I., Dillon, L., Li, Y., Hsieh, M., Hourigan, C. S., & Fitzhugh, C. D. (2020) · Blood · doi:10.1182/blood.2019004001 · Cited by 8
Singh, S., Pugliano, C. M., Honaker, Y., Laird, A., DeGottardi, M. Q., Lopez, E., Lachkar, S., Stoffers, C. M., Sommer, K., Khan, I., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101183 · Cited by 7
Sorel, N., Díaz-Pascual, F., Bessot, B., Sadek, H., Mollet, C., Chouteau, M., Zahn, M., Gil-Farina, I., Tajer, P., van Eggermond, M., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12071495 · Cited by 5
Research works printed but not linked: 1
- Pai, 2023, Universal survival and superior immune reconstitution after lentiviral gene therapy with low dose conditioning for X-linked SCID (SCID-X1), Mol. Ther., 31, 1
Cited by
Shu, J., Xie, X., Wang, S., Du, Z., Huang, P. Y., Chen, Y., & He, Z. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1595897 · Cited by 6
Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma
Azani, A., Ghassemifar, V., Mehrdad, Z., Saberivand, M., Pour, A. B., Tahmasebi, S., Gharedaghi, H., Sharafi, M., Foroozand, H., Meigoli, M. S. S., et al. (2025) · Cancer Reports · doi:10.1002/cnr2.70425 · Cited by 2
Reduced-intensity conditioning in LV-mediated gene therapy for Fabry disease targeting HSPCs
Khan, A., Barber, D. L., Foley, R., Keating, A., West, M. L., & Medin, J. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.054 · Cited by 1
Hurnikova, J., Venkatesan, J. K., Liu, W., Madry, H., Cucchiarini, M., & Petrovová, E. (2026) · SLAS TECHNOLOGY · doi:10.1016/j.slast.2026.100404 · Cited by 1
Eapen, M., & Williams, D. A. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102906 · Cited by 1
Self-citation
Metadata
- Authors
- Williams, D. A., Kohn, D. B., & Thrasher, A. J.
- Affiliations
- Boston Children's Hospital (US)
- University of California, Los Angeles (US)
- University College London (GB)
- Corresponding author
- Williams, David A.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2025-05
- Volume
- 33
- Issue
- 5
- Pages
- 2141-2153
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC12126793
- OpenAlex
- W4409101084
- Semantic Scholar
- 20b0e735fb8de73368c0e6f9fa8ee239c292dbe5
- Cited by
- 11
- References
- 90
- Citations by year
- 2026: 7 · 2025: 4
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- hematopoietic stem and progenitor cells, gene therapy, retroviral vectors, lentiviral vectors, HIV-based vectors, autologous transplantation, immunodeficiency, hemoglobinopathies, metabolic disorders, monogenic disorders, viral vectors, gene transfer efficiency
- MeSH terms
- Animals, Clinical Trials as Topic, Genetic Vectors, Hematopoietic Stem Cells, Humans, Retroviridae, Genetic Therapy, Lentivirus, Gene Transfer Techniques, Hematopoietic Stem Cell Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
